Arkolith/Insider Trading/EIGR/Form 4

Cory David A

President and CEO, DirectorEiger BioPharmaceuticals, Inc. (EIGR) · full profile →Form 4 · filed Mar 11, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 11, 2022Grant(A)47K—$0169K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 11, 2022Grant(A)281K—$0281K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-22-009256) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML